Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance
AbstractWhile addition of the first-approved protease inhibitors (PIs), telaprevir and boceprevir, to pegylated interferon (PEG-IFN) and ribavirin (RBV) combination therapy significantly increased sustained virologic response (SVR) rates, PI-based triple therapy for the treatment of chronic hepatitis C virus (HCV) infection was prone to the emergence of resistant viral variants. Meanwhile, multiple direct acting antiviral agents (DAAs) targeting either the HCV NS3/4A protease, NS5A or NS5B polymerase have been approved and these have varying potencies and distinct propensities to provoke resistance. The pre-clinical in vivo assessment of drug efficacy and resistant variant emergence underwent a great evolution over the last decade. This field had long been hampered by the lack of suitable small animal models that robustly support the entire HCV life cycle. In particular, chimeric mice with humanized livers (humanized mice) and chimpanzees have been instrumental for studying HCV inhibitors and the evolution of drug resistance. In this review, we present the different in vivo HCV infection models and discuss their applicability to assess HCV therapy response and emergence of resistant variants. View Full-Text
Share & Cite This Article
Mesalam, A.A.; Vercauteren, K.; Meuleman, P. Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. Viruses 2016, 8, 176.
Mesalam AA, Vercauteren K, Meuleman P. Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. Viruses. 2016; 8(6):176.Chicago/Turabian Style
Mesalam, Ahmed A.; Vercauteren, Koen; Meuleman, Philip. 2016. "Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance." Viruses 8, no. 6: 176.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.